Interellular crosstalk between cancer cells and cancer-associated fibroblasts via extracellular vesicles

Yutaka Naito1, Yusuke Yoshioka2 and Takahiro Ochiya2*

Abstract
Interellular communication plays an important role in cancer initiation and progression through direct contact and indirect interactions, such as via secretory molecules. Cancer-associated fibroblasts (CAFs) are one of the principal components of such communication with cancer cells, modulating cancer metastasis and tumour mechanics and influencing angiogenesis, the immune system, and therapeutic resistance. Over the past few years, there has been a significant increase in research on extracellular vesicles (EVs) as regulatory agents in intercellular communication. EVs enable the transfer of functional molecules, including proteins, mRNAs and microRNAs (miRNAs), to recipient cells. Cancer cells utilize EVs to dictate the specific characteristics of CAFs within the tumour microenvironment, thereby promoting cancer progression. In response to such “education” by cancer cells, CAFs contribute to cancer progression via EVs. In this review, we summarize experimental data indicating the pivotal roles of EVs in intercellular communication between cancer cells and CAFs.

Keywords: Cancer-associated fibroblasts, Extracellular vesicles, Cancer microenvironment, Intercellular communication, Non-coding RNA, Exosomes

Background
Although cancer cells arise from genetic mutations in normal cells, the malignant phenotypes of tumours are influenced by their surrounding tumour microenvironment (TME) [1]. The TME comprises various cellular components, including fibroblasts, endothelial cells, and inflammatory cells, as well as noncellular components, such as the extracellular matrix [1]. Accumulating evidence has demonstrated that among these TME components, cancer-associated fibroblasts (CAFs) modulate tumour metastasis and tumour mechanics and influence angiogenesis, the immune system, and therapeutic resistance [2]. Although CAFs are complex and include subtypes with protumorogenic and antitumour effects, several reports have indicated that CAFs are potential therapeutic targets for cancer treatment [2, 3]. Direct cell-to-cell contact and humoral factors such as cytokines and chemokines are considered the principal lines of communication between cancer cells and CAFs. However, recent studies have revealed that extracellular vesicles (EVs) are also regulatory players in such communication.

EVs are vesicles enclosed by a lipid bilayer membrane that include various bioactive molecules, such as proteins, mRNAs, metabolites, and microRNAs (miRNAs). Historically, EVs were initially considered “garbage bins” for exporting unnecessary intracellular components [4]. However, in 2007, Valadi et al. proposed that mRNAs packaged in EVs can be utilized for intercellular communication upon translation in recipient cells [5]. This discovery accelerated research on the role of EVs as novel regulatory agents.
intercellular communication tools. In particular, over the past ten years, there has been a striking expansion of EV research in cancer-related fields [6]. Various cancer-related factors packaged into EVs are transferred to recipient cells within proximal sites and distal metastatic niches. Intriguingly, Hoshino et al. indicated that integrin marks on EV surfaces could be considered a “zip-code” for delivery to specific organs [7], suggesting that cancer cells utilize EVs to confer specific features on cells in distal organs to support metastasis. In addition, cells within the TME, particularly CAFs, also regulate tumour progression, such as metastasis, by transferring EVs to cancer cells [6]. These findings imply that EVs derived from cancer cells and host-derived CAFs are involved in the formation of a suitable TME that promotes cancer progression.

In addition to the striking functions of EVs in intercellular communication, these vesicles can be detected in various body fluids, such as blood, saliva, and urine [8]. Therefore, EVs are attractive targets for improving cancer treatment and diagnosis. How do cancer cells utilize EVs to dictate the function and phenotypes of surrounding TME components to support cancer progression? This review will focus on recent advances in the interplay between cancer cells and CAFs and summarize the current knowledge regarding the functional role of EVs in the interplay between cancer cells and fibroblasts within the TME.

**Nomenclature of extracellular vesicles**

There are various subtypes of EVs with differential components and biogenesis processes. They are traditionally classified into exosomes, ectosomes, and apoptotic bodies based on origin and size [4, 9]. Exosomes originate from the exocytosis of multivesicular bodies (MVBs) [9, 10]. Ceramide-dependent pathways and endosomal sorting complex required for transport (ESCRT) machinery partially regulate exosome release. Exosomes can contain the following proteins: membrane transport and fusion proteins (GTPase, annexins, and flotillin), tetraspanins (CD9, CD63, and CD81), heat shock proteins (Hsc70 and Hsp90), MVB-related proteins (Alix and TSG101), lipid proteins and phospholipases. Microvesicles are generated directly from budding of the plasma membrane [11]. Microvesicles can be enriched in some lipid components and phosphatidylserine [12]. Apoptotic bodies are generated during apoptosis. Thus, they contain intracellular fragments such as organelles, membranes, and cytosolic and nuclear fragments [13, 14]. However, it is still difficult to distinguish various types of EVs because of the lack of specific protein markers for each subtype. Thus, the expert consensus in EV research encourages the use of operational names unless specific and reliable EV markers of subcellular origin can be established [9]. (a) Physical characteristics, such as the size or density of EVs: small EVs (sEVs: < 100 nm or < 200 nm) and large and/or medium EVs (m/lEVs: > 200 nm). (b) Biochemical composition, such as positivity of staining for CD63, CD81, and Annexin A5. (c) Description of conditions or cells of origin, such as from podocytes and apoptotic bodies. In this review, to avoid confusion, we use the term EVs for all subtypes of membrane vesicles in the extracellular space rather than specific terms such as exosomes.

**What are CAFs?**

To discuss the functional role of EVs in cancer-CAF interactions, we first need to define CAFs. CAFs are fibroblasts within the tumour stroma that can originate from many cell types, including resident fibroblasts, adipocytes, bone marrow-derived mesenchymal stem cells (BM-MSCs), and endothelial cells. The subtypes of CAFs include myofibroblast-like phenotypes similar to the features of activated fibroblasts during wound healing [15]. Many researchers, therefore, utilize adopted activated fibroblast markers such as alpha-smooth muscle actin (α-SMA) for the detection of CAFs [15]. However, recent promising studies and single-cell technologies have indicated that CAFs comprise diverse subtypes with distinct characteristics [16, 17]. Thus, conventional markers of CAFs are likely insufficient to detect all CAF subtypes within tumour tissue [18]. These findings are consistent with the fact that normal fibroblasts are also heterogeneous and lack unique markers that are not expressed in other cell types [2]. Although the precise definition of CAFs is still challenging, CAFs are practically considered morphologically elongated cellular components that are negative for epithelial, endothelial and leukocyte markers within tumour tissues [2]. To exclude the possibility of cancer cells undergoing epithelial–mesenchymal transition (EMT), CAFs are also defined as cells lacking genetic mutations found within the cancer cells [2].

The origin of CAFs and the signalling that mediates CAF heterogeneity remain controversial. Given the diverse subtypes in the normal fibroblast population, CAF subtypes may reflect their original tissue background. Indeed, in breast cancer, Raz et al. demonstrated that PDGFR-α-positive and PDGFR-α-negative subsets of CAFs are generated from BM-MSCs and resident fibroblasts, respectively [19]. They utilized a unique in vivo model involving BM implantation from GFP-expressing mice to MMTV-PyMT transgenic mice to track the cellular fate of BM-MSCs within the tumour mass. This study showed that BM-MSC-derived CAFs are negative for PDGFR-α expression and enhance angiogenesis and tumour growth. In contrast, in pancreatic ductal adenocarcinoma (PDAC), Tuveson’s group showed that pancreatic stellate cells differentiate...
into two subsets of CAFs, inflammatory CAFs (iCAFs) and myofibroblastic CAFs (myCAFs) [20]. They also showed that IL-1 signalling induces iCAFs, but TGF-β signalling antagonizes this pathway, leading to myCAF differentiation [21]. Notably, these CAF subtypes are likely responsible for distinct functions for cancer progression, such as immunomodulatory functions and extracellular matrix (ECM) remodelling [19, 20]. These findings collectively imply that tissue environmental background and cancer-derived factors determine CAF complexity.

Diverse functions of CAFs in tumour progression have been reported. One substantial function of CAFs is as a source of various types of growth factors and chemokines, such as transforming growth factor-beta (TGF-β) [15, 22], CXC-chemokine ligand 12 (CXCL12)/SDF-1 [23], and HGF [24]. These CAF-derived factors promote an aggressive phenotype of cancer cells with invasive and metastatic behaviour, including the induction of EMT. The CD10 and GPR77 double-positive CAF subset secretes IL-6 and IL-8, sustaining cancer stemness and promoting chemoresistance [25]. In addition to direct effects on cancer cell behaviours, CAFs also generate VEGF to induce the angiogenesis of endothelial cells. CAFs also produce IL-6 and CXCL9 and regulate the immunosuppressive or immuno-promoting functions of inflammatory cells. The newly identified CAF subtype, antigen-presenting CAFs (apCAFs), can mediate CD4+ regulatory T-cell activation and CD8+ T-cell suppression [26]. These findings indicate that CAFs can mediate the function of both cancer cells and surrounding stromal cells within the TME.

Another essential function of CAFs is remodelling the extracellular matrix within the TME. CAFs produce ECM-related molecules, such as collagens and metalloproteases, which lead to the deposition and remodelling of the ECM. This remodelled ECM causes increased tissue stiffness, triggering proliferation signals in cancer cells. The increased tissue stiffness also promotes blood vessel collapse, reducing drug delivery. Matrix stiffening within tumour tissue also enhances the activation of YAP in normal fibroblasts and CAFs, which is involved in CAF generation and maintenance [27]. In addition, the metalloprotease produced by CAFs generates migratory tracks that allow cancer cell invasion [28]. Since CAFs can mediate the migration of cancer cells via E-cadherin/N-cadherin interactions [29], CAFs may be able to guide cancer cell invasion.

**Cancer-derived EVs can dictate preferable CAF characteristics for cancer progression**

Over the past few years, there has been an increasing number of reports regarding the functional interplay of EVs in communication between cancer cells and CAFs (Tables 1 and 2). In this review, to better understand the intercellular crosstalk between cancer cells and CAFs via EVs, we focused on the papers that investigated EV components and revealed their functions on the recipient cells.

Many researchers have reported how CAFs are generated by cancer cells. Both direct contact and indirect interaction between cancer cells and CAFs are essential to maintain CAF characteristics. Among these interactions, TGF-β signalling is a well-established factor for activating fibroblasts and generating CAFs [2]. In addition to these mechanisms, cancer cells utilize EVs to generate CAFs (Fig. 1 and Table 1). The first report on cancer-derived EVs related to CAF induction was published by Webber et al., who showed that TGF-β was expressed on the surface of EVs derived from prostate cancer and mesothelioma cell lines [30, 31]. TGF-β on these cancer-derived EVs triggered the TGF-β/SMAD3 signalling pathway in recipient fibroblasts and induced myofibroblast-like phenotypes, including the expression of α-SMA and fibroblast growth factor 2 (FGF2) [30]. Recently, Huang et al. also showed that TGF-β in EVs generates CAFs via a noncanonical fibronectin-dependent pathway [32]. These reports demonstrated that EVs are responsible for some of the signalling previously thought to be carried out by growth factors. In studying triple-negative breast cancer, Sung et al. utilized an experimental model expressing integrin beta 4 (ITGB4) to determine the effect of EVs on the properties of CAFs [33]. Cancer-derived EVs transfer ITGB4 and induce BCL2 interacting protein 3 like (BNIP3L)-dependent mitophagy and glycolysis in CAFs. They also showed that the overexpression of ITGB4 in CAFs promotes breast cancer cell proliferation, EMT, and invasion [33]. Yan et al. demonstrated the reprogramming of glucose and glutathione metabolism in CAFs induced by miR-105 transferred by metastatic breast cancer cell-derived EVs [34]. Targeting of MXI1 by miR-105 activates MYC, the essential driver of metabolic reprogramming in CAFs. Long non-coding RNAs (lncRNAs) are also transferred from cancer cells to fibroblasts. Since the exchange of metabolites and amino acids is one mechanism of interplay between cancer cells and CAFs [35–37], it is highly plausible that cancer cells utilize EVs to dictate metabolic reprogramming in CAFs and thus construct a preferable microenvironment for their progression.

Cancer cell properties such as TP53 gene mutation also affect EV components and have consequences on CAF generation [38–41]. Novo et al. demonstrated that TP53-mutant cancer cells mediate integrin trafficking in fibroblasts via EVs and promote the deposition of a proinvasive ECM [38]. Although they did not focus on molecules encapsulated in EVs, this finding implies that EVs are involved in matrix remodelling within the TME via
| Contents of cancer-derived EVs | Tumour type | EV donor (From) | EV recipient (To) | Functions of EVs on the CAF properties | Reference |
|-------------------------------|-------------|----------------|------------------|----------------------------------------|-----------|
| Proteins                      |             |                |                  |                                        |           |
| Integrins                     | Breast cancer | Pancreatic cancer | Cancer cells | CAFs | Up-regulates S100 gene expressions and promote cell growth and migration | [7] |
| TGF-β                         | Bladder cancer |                |                  | Generate CAFs by activating SMAD-dependent pathway | [72] |
| Integlin αv and β1            | Breast cancer | Integrin αv and β1 | CD63-positive EVs | Induce CAF-like phenotypes in the fibroblasts. Galectin-3 might regulate the loading integrin αv and β1 in EVs. | [176] |
| ITGB4                         | Breast cancer |                |                  | Induces BCL2 interacting protein 3 like (BNIP3L)-dependent mitophagy and glycolysis. | [33] |
| Sphingosine 1                 | Breast cancer |                |                  | Sphingosine 1 derived from cancer cells may stimulate ERK-1/2 signalling and DNA synthesis | [73] |
| Survivin                      | Breast cancer |                |                  | Generate CAFs with myofibroblastic features through inducing SOD1 expression to promote tumour proliferation and metastasis | [74] |
| Wnt2B                         | Cervical cancer |                |                  | Generate CAFs through activating Wnt/β-catenin signalling | [75] |
| HSPC111                       | Colorectal cancer |                |                  | Reprogramming lipid metabolism in CAFs to promote cancer metastasis. | [180] |
| TIMP-1                        | Colorectal cancer |                |                  | Cancer-derived EVs transfer TIMP-1 to induced ECM remodelling in the fibroblasts. | [178] |
| LMP1                          | Epstein-Barr virus (EBV)-associated Nasopharyngeal carcinoma |                |                  | Generate CAFs through NF-kB signalling and change aerobic glycolysis and autophagy in CAFs | [76] |
| PKM2                          | Gastric cancer |                |                  | Generate CAFs by PKM2 nuclear translocation inducing NF-kB signalling | [77] |
| TGF-β                         | Head and neck squamous cell carcinoma |                |                  | Generate CAFs through activation canonical TGF-β signalling pathway | [32] |
| PKM2                          | Hypoxic resistant lung cancer cells |                |                  | Induce metabolic reprogramming in CAFs | [78] |
| IGF2                          | Liver cancer |                |                  | Fluid shear stress-induced cancer cell medium promoted the activation and proliferation of CAFs via activating PI3K/AKT signalling pathway. | [172] |
| α-SMA                         | Lung cancer |                |                  | Cancer-derived EV transfer α-SMA in both lung cancer cell line and fibroblasts. These EVs also promote cell proliferation and inhibit apoptosis. | [79] |
| TGF-β                         | Malignant ascite from gastric cancer and ovarian cancer |                |                  | TGF-β in EVs may induce CAF phenotypes in peritoneal mesothelial cells | [80] |
| Contents of cancer-derived EVs | Tumour type | EV donor (From) | EV recipient (To) | Functions of EVs on the CAF properties | Reference |
|-------------------------------|-------------|----------------|------------------|---------------------------------------|-----------|
| HSP90 and p-IKKα/β complex    | Melanoma    |                |                  | Promote the proangiogenic capacity via activating NF-κB signalling to induce CXCL1 expression in CAFs. | [173]     |
| TGF-β                         | Mesothelioma| Colorectal cancer | Prostate cancer | Triger the myofibroblast differentation | [30]      |
| FAP and EBV-encoded latent membrane protein 1 (LMP1) | Nasopharyngeal carcinoma | | | | |
| COL6A1                        | Osteosarcoma |                |                  | Generate CAFs via enhancing YAP1 signalling and increasing FAP expression. | [177]     |
| Gain-of-function p53          | Ovarian cancer |                |                  | Instigate CAF phenotypes in fibroblasts through the Nrf2-dependent pathway | [39]      |
| Annexin A1                   | Pancreatic cancer |                |                  | Induce myofibroblasts features in the fibroblasts and endothelial cells | [82]      |
| Lin28B                        | Pancreatic cancer |                |                  | Generate CAFs from pancreatic stellate cells through activating let-7/HMG2/PDGFRβ axis. | [83]      |
| Hyal1                         | Prostate cancer |                |                  | Stimulate fibroblast chemotaxis by the increased adhesion and activating FAK signalling | [84]      |
| TGF-β                         | Prostate cancer |                |                  | Triger the myofibroblast differentation and promote cancer growth and angiogenesis | [31]      |
| C-terminal Dsg2               | Squamous cell carcinoma | | | | |
| Coding RNAs                  | Inflammation-inducing mRNAs | Melanoma | Cancer cells | CAFs | Induce CAF subtype with inflammatory signatures in within metastatic niche | [47]      |
| non-coding of transposable RNAs | miR-105 | Breast cancer | Cancer cells | CAFs | Reprogram glucose and glutamine metabolism to fuel adjacent cancer cells | [34]      |
| miR-105 and miR-204           | Breast cancer |                |                  | Cancer-derived EVs might transfer miR-105 and miR-204 and suppress RAGC expression in fibroblasts. | [175]     |
| miR-122                       | Breast cancer |                |                  | Down-regulate glucose consumption of fibroblasts | [63]      |
| miR-125b                      | Breast cancer |                |                  | Generates CAFs from resident fibroblasts through targeting TP53INP1 expression | [43]      |
| miR-130b-3p                   | Breast cancer |                |                  | Generate CAFs via targeting SPIN90 in fibroblasts and facilitate cancer progression. | [179]     |
| Contents of cancer-derived EVs | Tumour type                      | EV donor (From) | EV recipient (To) | Functions of EVs on the CAF properties                                                                 | Reference |
|-------------------------------|----------------------------------|----------------|------------------|-----------------------------------------------------------------------------------------------------|-----------|
| miR-185-5p, miR-652-5p, and miR-1246 | Breast cancer                   |                |                  | Three miRNAs in cancer-derived EVs can be involved in the induction of CAF phenotypes in normal fibroblasts. | [171]     |
| miR-370-3p                    | Breast cancer                   |                |                  | Induce fibroblast activation through CYLD/NF-κB signalling and promote cancer progression             | [86]      |
| Decreased miR-34c             | Cholangiocarcinoma              |                |                  | Enhancing Wnt1 expression in fibroblasts and generate CAFs. miR-34 directly target Wnt1 expression. | [87]      |
| miR-146a                      | Chronic lymphocytic leukaemia    |                |                  | Generate CAFs by targeting USP16 expression in fibroblasts                                          | [88]      |
| miR-10a                       | Colorectal cancer (SW480 cell line) |                |                  | Inhibit migration and expression of IL-6 and IL-8 expression in fibroblasts                          | [89]      |
| miR-1249-5p, miR-6737-5p, and miR-6819-5p | Colorectal cancer |                |                  | EVs derived from cancer cells with p53 shRNA generate CAFs. miRNAs in EVs may contribute to induction of CAF phenotype in fibroblasts. | [44]      |
| miR-146a-5p and miR-155-5p     | Colorectal cancer               |                |                  | Generate CAFs via targeting SOCS1 and ZBTB2 to activate JAK2-STAT3/NF-κB signalling. CXCL12/CXCR7 is associated with these miRNA expressions in cancer cells. | [181]     |
| miR-200 family                | Colorectal cancer               |                |                  | CRC cells with an epithelial phenotype but not a mesenchymal phenotype secrete miR-200 family members via EVs to attenuate TGF-β-mediated CAF features by targeting ZEB1 in normal fibroblasts. | [45]      |
| miR-4534                      | Colorectal cancer               |                |                  | Suppress autophagy to induce CAF phenotypes in fibroblasts. EV miR-4534 targets ATG2B expression.    | [182]     |
| miR-27a                       | Gastric cancer                  |                |                  | Generate CAFs to support cancer migration and invasion.                                             | [90]      |
| Several miRNAs including miR-193b | Gastric cancer                |                |                  | Induce CAF subtype with inflammatory signatures                                                      | [46]      |
| miR-192, miR-215              | Head and neck squamous cell carcinoma |                |                  | Generate CAFs through targeting CAV1 to induce TGF-β/SMAD signalling.                                | [91]      |
| miR-9-5p                      | Head and neck squamous cell carcinoma |                |                  | HPV-positive head and neck squamous cell carcinoma cells secrete miR-9-5p via EVs. EV miR-9-5p suppresses NOX4 expression to inhibit the induction of TGF-β-mediated CAF phenotype in fibroblasts. | [174]     |
| miR-21                        | Hepatocellular carcinoma        |                |                  | Generate CAFs from hepatocyte stellate cells through activating PDK1/Akt signalling                  | [92]      |
| Table 1 (continued) |
|---------------------|
| Contents of cancer-derived EVs | Tumour type | EV donor (From) | EV recipient (To) | Functions of EVs on the CAF properties |
| miR-1247-3p | Hepatocellular carcinoma | Generate CAFs expressing inflammatory genes through targeting B4GALT3 to activate β1 integrin/NF-κB signalling | [49] |
| miR-181d-5p | Hepatoma cell | May induce CAF state via targeting SOCS3 expression in bone-marrow stem cells (BMSCs) | [93] |
| miR-3473b | Lewis lung carcinoma | Generate inflammatory gene expressing CAFs through activating NF-κB signalling | [94] |
| miR-142-3p | Lung cancer | EVs derived from cancer cells with miR-142-3p over-expression generate CAFs via non-canonical TGF-β signalling | [96] |
| miR-210 | Lung cancer | Generate CAFs expressing proangiogenic factors through activating JAK2/STAT3 signalling | [95] |
| IncRNA Gm26809 | Melanoma | Generate CAF properties in NIH3T3 fibroblasts | [97] |
| miR-155 | Melanoma | Generate CAFs expressing proangiogenic factors through inhibiting SOCS1 to activate JAK2/STAT3 signalling | [99] |
| miR-155 and miR-210 | Melanoma | Increase aerobic glycolysis and decrease oxidative phosphorylation in fibroblasts | [98] |
| miR-375 | Merkel cell carcinoma | Generate CAFs through targeting RBPJ and p53 expression | [100] |
| miR-21 | Mouse melanoma cell | Promote the invasion activity of fibroblasts through targeting TIMP-3 expression | [101] |
| IncRNA (LncRNA-CAF) | Oral squamous cell carcinoma | Stimulate IL-33 expression and CAF phenotypes in fibroblasts to influence CAF generation from other surrounding fibroblasts and promotes tumour growth | [102] |
| miR-630 | Ovarian cancer | Generate CAFs through targeting KLF6 and activating NF-κB signalling pathway | [103] |
| miR-155 | Pancreatic cancer | Induce cancer-associated fibroblast like phenotype through repressing TP53P1 | [104] |
| Several miRNAs including miR-1246 and miR-1268 | Rhabdomyosarcoma | Rhabdomyosarcoma-derived EVs promote cell growth and stimulate angiogenic capacities in fibroblasts | [105] |
| Others | | | |
| Not investigated | Bladder cancer | Cancer-derived EVs induce inflammatory CAFs (iCAFs) | [48] |
| miR-1246, TGF-β, β-catenin, IL-6, p-STAT3 | Colorectal cancer | Cancer-derived EVs generate CAFs. But the precise mechanism of how molecules in EVs induce CAF signatures in fibroblasts is not addressed | [108] |
| Contents of cancer-derived EVs | Tumour type                              | EV donor (From) | EV recipient (To) | Functions of EVs on the CAF properties                                                                 | Reference |
|--------------------------------|------------------------------------------|----------------|-------------------|-------------------------------------------------------------------------------------------------------|-----------|
| Not investigated               | Colorectal cancer                        |                |                   | Stimulate migration capacity of CAFs via activating Rho-Fak signalling                                   | [106]     |
| Not investigated               | Colorectal cancer                        |                |                   | Cancer-derived EVs generate CAFs to acquire the capacity to invade matrix and to support cancer invasion.| [107]     |
| Not investigated               | Experimentally induced cancer stem cells (Piwil2-CSC) |                |                   | Generate CAFs and enhance cell migration and invasion in CAFs                                         | [109]     |
| Not investigated               | Gastric cancer                           |                |                   | Generate CAFs from pericytes through activating PI3K/AKT and MEK/ERK signalling pathways                | [110]     |
| Not investigated               | Gastric cancer                           |                |                   | Generate CAFs through canonical TGF-β signalling pathway                                               | [111]     |
| Not investigated               | Lung cancer                              |                |                   | Mediate immunomodulate effect via inducing PD-L1                                                      | [112]     |
| Not investigated               | Lung cancer                              |                |                   | Cancer cells with TP53 mutation mediate the integrin trafficking in the fibroblasts via EVs and promote the deposition of invasive ECMs | [38]      |
| Not investigated               | Ovarian cancer                           |                |                   | Cancer-derived EVs instigate cell adhesion and migration capacity in CAFs                              | [67]      |
| Not investigated               | Prostate cancer                          |                |                   | Cancer-derived EVs stimulate prometastatic factors including brain-derived neurotrophic factor and CXCL12. | [113]     |
| Not investigated               | Salivary adenoid cystic carcinoma        |                |                   | Induce the capacity to enhance cancer invasion and NGF expression in human periodontal ligament fibroblasts | [114]     |
| Contents of CAF-derived EVs | Tumour type | EV donor (From) | EV recipient (To) | Functions of CAF-derived EVs on cancer progression | References |
|----------------------------|-------------|----------------|------------------|--------------------------------------------------|------------|
| Proteins                   |             |                |                  |                                                  |            |
| CD81                       | Breast cancer | CAFs           | Cancer cells     | Enhance cancer motility and metastasis through activating Wnt-planar cell polarity (PCP) signalling pathway | [50]       |
| Extracellular matrix proteins and ADAM10 | Breast cancer |                |                  | Induce aldehyde dehydrogenase expression in cancer cells through Notch activation and enhance motility through the GTPase RhoA. | [115]      |
| Wnt10b                     | Breast cancer | CAFs with low p85α expression | Cancer cells via EVs and promote cancer progression |                                             | [116]      |
| Amphiregulin                | Colorectal cancer |              |                  | TGF-β-induced CAF model secretes Amphiregulin via EVs and promote cell proliferation in EGF-dependent patient-derived organoids | [118]      |
| Wnt3a                      | Colorectal cancer |                |                  | Expansion of cancer stem cell to enhance chemo resistance | [117]      |
| Sonic Hedgehog (Shh)       | Esophageal squamous cell carcinoma |             |                  | Promote cancer cell proliferation. CAF-derived EVs may transfer Shh to enhance tumour growth. | [119]      |
| Annexin A6                 | Gastric cancer |                |                  | Activate FAK-YAP signalling through stabilizing integrin β1 to enhance drug resistance. | [120]      |
| CD9                        | Gastric cancer |                |                  | CAFs secrete CD-9 positive EVs and stimulate diffuse-type GC migration. | [51]       |
| INHBA and THBS1/2          | Gastric cancer |                |                  | INHBA and THBS1/2 are associated with aggressive property of gastric cancer. HSF-1, master regulator of these molecules, may contribute to the loading of these molecules in MEF- and CAF-derived EVs. | [121]      |
| Gremlin-1                  | Hepatocellular carcinoma |                |                  | Promote EMT and sorafenib resistance via activating Wnt/β-catenin signalling pathway. | [200]      |
| SLPI                       | Ovarian cancer |                |                  | Promote cancer progression by activating PI3K and MAPK signalling pathways. | [194]      |
| TGF-β1                     | Ovarian cancer |                |                  | Promote EMT in cancer cells through inducing canonical TGF-β signalling. | [122]      |
| Annexin A6                 | Pancreatic cancer |                |                  | ANXA6- and CD9-double positive CAF-derived EVs facilitate p38 MAPK signal activation to enhance migratory ability in PDAC cells. | [52]       |
| Galectin-1                 | Prostate cancer, Pancreatic cancer, Melanoma |                |                  | CAF-derived galectin-1 may contribute to cancer migration. | [123]      |
| Coding RNAs                |             |                |                  |                                                  |            |
| SNAI1 mRNA                 | Lung cancer | CAFs           | Cancer cells     | Transfer SNAI1 mRNA and promote EMT in cancer cells. | [124]      |
| non-coding of transposable RNAs |             |                |                  |                                                  |            |
| Contents of CAF-derived EVs | Tumour type     | EV donor (From) | EV recipient (To) | Functions of CAF-derived EVs on cancer progression                                                                 | References |
|---------------------------|----------------|----------------|------------------|----------------------------------------------------------------------------------------------------------------|------------|
| LINC00355                 | Bladder cancer | CAFs           | Cancer cells     | Function as a sponge of miR-15a-5p and increase HMGA2 expression to promote cancer progression                   | [125]      |
| LINC00355                 | Bladder cancer | CAFs           | Cancer cells     | miR-1-3p expression is decreased in CAF-derived EVs. These CAF-derived EVs promote cancer progression. miR-1-3p targets GLIS1 expression in cancer cells. | [133]      |
| Decreased miR-4516        | Breast cancer  | Decreased miR-4516 | BREAST CANCER | miR-4516 expression is decreased in CAF-derived EVs and also promote cancer progression. miR-4516 targets FOSL1 to promote cancer progression. | [131]      |
| Decreased miR-7641        | Breast cancer  | Decreased miR-7641 | BREAST CANCER | miR-7641 expression is decreased in CAF-derived EVs. These CAF-derived EVs can induce cancer stemness and metabolic reprogramming. | [132]      |
| IncRNA SNHG3              | Breast cancer  | IncRNA SNHG3   | BREAST CANCER | CAF-derived SNHG3 act as sponge for miR-330-5p expression to increase PKM protein expression results in metabolic reprogramming in cancer cells. | [62]       |
| miR-16 and miR-148a       | Breast cancer  | FAK-null CAFs  | Breast cancer    | FAK-null CAFs suppress cancer metastasis, and this CAF-derived EVs can partially contribute to the reduced tumour cell activities and metastasis. | [129]      |
| miR-181d-5p               | Breast cancer  | CD63-positive CAFs | Breast cancer | miR-181d-5p expression is decreased in CAF-derived EVs. These CAF-derived EVs can promote cancer cell migration and invasion through targeting CDX2 and HOXAS5 to induce EMT in cancer cells. | [130]      |
| miR-18b                   | Breast cancer  | miR-18b        | Breast cancer    | miR-18b expression is decreased in CAF-derived EVs. These CAF-derived EVs can promote cancer cell proliferation through targeting Transcription Elongation Factor A Like 7 (TCEAL7) expression in cancer cells. | [195]      |
| miR-22                    | Breast cancer  | miR-22         | Breast cancer    | CD63-positive CAF-derived EVs express miR-22 and promote Tamoxifen resistance in cancer cells through targeting SFRS1 expression. | [58]       |
| miR-3613-3p               | Breast cancer  | miR-3613-3p    | Breast cancer    | miR-3613-3p expression is decreased in CAF-derived EVs. These CAF-derived EVs can promote cancer cell proliferation through targeting SOCS2 expression in cancer cells. | [128]      |
| miR-500a-5p               | Breast cancer  | miR-500a-5p    | Breast cancer    | miR-500a-5p expression is decreased in CAF-derived EVs. These CAF-derived EVs can promote cancer cell proliferation and metastasis through targeting USP expression. | [127]      |
| miR-92                    | Breast cancer  | miR-92         | Breast cancer    | miR-92 expression is decreased in CAF-derived EVs. These CAF-derived EVs can promote cancer cell proliferation and metastasis through targeting USP expression. | [58]       |
| Contents of CAF-derived EVs          | Tumour type | EV donor (From) | EV recipient (To) | Functions of CAF-derived EVs on cancer progression                                                                 | References |
|-------------------------------------|-------------|----------------|------------------|---------------------------------------------------------------------------------------------------------------|------------|
| Non-coding of transposable RNAs     | Breast cancer |                |                  | Stimulate RIG-I recognition to activate STAT1 in cancer cells.                                                | [53]       |
| miR-1323                            | Cervical cancer |                |                  | Promote radioresistance via targeting PA-BPN1 and activating Wnt/β-catenin signalling pathway.                | [198]      |
| circN4BP2L2                         | Colorectal cancer |                |                  | Promote cancer cell proliferation and metastasis. circN4BP2L2 in EVs targets miR-664b-3p to induce HMGB3 expression | [188]      |
| IncRNA CCAL                         | Colorectal cancer |                |                  | Promotes Oxaliplatin resistance in CRC cells via stabilizing human antigen R (HuR) mRNA to increase β-catenin signalling | [56]       |
| IncRNA H19                          | Colorectal cancer |                |                  | Promote Cancer stemness and chemoresistance through targeting miR-141 expression and activating β-catenin signalling | [137]      |
| IncRNA LINC00659                    | Colorectal cancer |                |                  | Act as an RNA sponge for miR-342-3p expression to induce ANXA2 expression and promote EMT in cancer cells.    | [142]      |
| LncRNA SNHG3                        | Colorectal cancer |                |                  | Promote cell proliferation via targeting miR-34b-5p to induce HOXC6 expression in cancer cell.                | [190]      |
| miR-135b-5p                         | Colorectal cancer |                |                  | Promote tumour angiogenesis via targeting FOXO1 expression in cancer cell.                                    | [189]      |
| miR-135b-5p                         | Colorectal cancer |                |                  | Might promote tumour angiogenesis and cancer cell proliferation via TXNIP expression.                         | [202]      |
| miR-17-5p                           | Colorectal cancer |                |                  | Promote cancer progression through targeting RUNX3 to activate MYC/TGF-β axis in cancer cells                 | [134]      |
| miR-181-5p                          | Colorectal cancer |                |                  | Promote 5-FU resistance via targeting neurocalcin δ (NCALD) expression in colorectal cancer cells.            | [193]      |
| miR-21                              | Colorectal cancer |                |                  | Promote liver metastasis via transfering miR-21 and influence cell proliferation and chemoresistance.        | [138]      |
| miR-224-5p                          | Colorectal cancer |                |                  | Involve in cancer progression through targeting SLC4A4 expression.                                           | [141]      |
| miR-24                              | Colorectal cancer |                |                  | Enhance methotrexate resistance of cancer cells via targeting CDX2 to regulate HEPH expression.               | [139]      |
| miR-590-3p                          | Colorectal cancer |                |                  | Promote the radioresistance in cancer cells through targeting CLCA4 to activate PI3K/AKT signalling pathway and reduce expressions of cleaved-caspase 3 and cleaved-PRAP | [140]      |
| Contents of CAF-derived EVs | Tumour type                  | EV donor (From) | EV recipient (To) | Functions of CAF-derived EVs on cancer progression                                                                                      | References |
|---------------------------|------------------------------|-----------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------|------------|
| miR-92a-3p                | Colorectal cancer            |                 |                   | Promote cancer metastasis and chemotherapy resistance through targeting FBXW7 and MOAP1 expression                                       | [136]      |
| miR-93-5p                 | Colorectal cancer            |                 |                   | Targeting FOXA1 and induce TGFβ3b and promote radioresistance                                                                      | [135]      |
| Decreased miR-320a        | Endometrial cancer           |                 |                   | miR-320a expression is decreased in CAF-derived EVs and promote cancer progression. miR-320a targets HIF1α expression in cancer cells      | [143]      |
| Decreased miR-148b        | Endometrial cancer           |                 |                   | miR-148b expression is decreased in CAF-derived EVs to enhance cancer metastasis through inducing EMT. miR-148b in EVs may target DNMT1. | [144]      |
| IncRNA NEAT1              | Endometrial cancer           |                 |                   | Act as an RNA sponge for miR-26a/b-5p expression to induce YKL-40 expression via STAT3 signalling and enhance cancer progression.        | [145]      |
| LINCO1410                 | Esophageal cancer            |                 |                   | Promote EMT via targeting miR-122 and inducing PKM2 expression.                                                                        | [199]      |
| miR-21                    | Esophageal squamous cell carcinoma |             |                   | CAF-derived miR-21 cooperates with IL-6 to induce monocyctic myeloid-derived suppressor cells (M-MDSC), resulting in osmotic resistance regulation in cancer cells. | [146]      |
| Decreased miR-34          | Gastric cancer               |                 |                   | miR-34 expression is decreased in CAF-derived EVs and promote cancer progression.                                                      | [147]      |
| IncRNA circ_0088300       | Gastric cancer               |                 |                   | Act as an RNA sponge for miR-1305 expression to promote cancer progression. KHOBRS3 contributes to circ_0088300 transfer via CAF-derived EVs. | [150]      |
| miR-199a-5p               | Gastric cancer               |                 |                   | Promote cancer progression by targeting FKB5 expression and activating mTORC1 signalling in cancer cells.                              | [201]      |
| miR-522                   | Gastric cancer               |                 |                   | Suppress ferroptosis via targeting ALOX15 expression and promote chemoresistance. hnRNPA1 and USP7 are associated with miR-522 secretion via CAF-derived EVs. | [148]      |
| MMP-11 and Decreased miR-139 | Gastric Cancer             |                 |                   | Transfer MMP-11 to promote cancer cell progression. miR-139 expression is decreased in CAF-derived EVs and also promote cancer progression. miR-139 may target MMP11. | [149]      |
| Contents of CAF-derived EVs | Tumour type | EV donor (From) | EV recipient (To) | Functions of CAF-derived EVs on cancer progression | References |
|-----------------------------|-------------|----------------|------------------|------------------------------------------------|------------|
| Decreased miR-3188         | Head and neck cancer | miR-3188 expression is decreased in CAF-derived EVs to promote cell proliferation and inhibit apoptosis in cancer cells. EV-derived miR-3188 targets BCL2 expression. | [151] |
| miR-196a                   | Head and neck cancer | Promote cisplatin resistance via targeting CDXN1B and ING5 expression. | [152] |
| Decreased miR-150-3p       | Hepatocellular carcinoma | miR-150-3p expression is decreased in CAFs and their EVs to promote cancer cell progression. | [153] |
| Decreased miR-29b          | Hepatocellular carcinoma | miR-29b expression is decreased in CAF-derived EVs and promote cancer migration and invasion. miR-29b may target DNMT3b to modulate EMT in cancer cells. | [154] |
| Decreased miR-320a         | Hepatocellular carcinoma | miR-320a expression is decreased in CAF-derived EVs. These CAF-derived EVs promote cancer progression. miR-320a targets PBX1 expression in cancer cells. | [155] |
| Decreased let-7a-5p        | Lung cancer | Sulfonylurea receptor 1 (SUR1) expressing cancer cells decreased let-7a-5p expression in their EVs to induce CAFs. Mechanistically, let-7a-5p targets TGFBR1 to inactivate the TGF-β signalling in fibroblasts. | [184] |
| IncRNA OIP5-AS             | Lung cancer | Export OIP-AS to suppress miR-142-5p and induce PD-L1 expression. EVs can be involved in immune tolerance of tumour. | [183] |
| IncRNA SNHG12              | Lung cancer | Promote cisplatin resistance by binding to HuR to facilitate RNA stability and XIAP expression. | [187] |
| IncRNA TUG1                | Lung cancer | Promote cancer cell migration, invasion, and glycolysis. TUG1 in EVs may target miR-524-5p to induce SIX1 expression. | [185] |
| miR-103a-3p                | Lung cancer | Suppress apoptosis and promote cisplatin resistance through targeting Bak1 expression. Pum2 contributes to miR-103a loading into CAF-derived EVs. | [159] |
| miR-130a                   | Lung cancer | Cisplatin-induced miR-130a is transferred by CAF-derived EVs and promotes chemoresistance in cancer cells. PUM2 contributes to miR-130a packaging into CAF-derived EVs. | [158] |
| miR-20a                    | Lung cancer | Promote cancer cell proliferation and cisplatin resistance via targeting PTEN expression in non-small cell lung cancer cells. | [192] |
## Table 2 (continued)

| Contents of CAF-derived EVs | Tumour type | EV donor (From) | EV recipient (To) | Functions of CAF-derived EVs on cancer progression | References |
|-----------------------------|-------------|----------------|-------------------|--------------------------------------------------|------------|
| miR-210                     | Lung cancer |                |                   | Promote cancer cell migration and invasion through targeting UPF1 to induce EMT in cancer cells | [156]      |
| miR-369                     | Lung cancer |                |                   | Promote cancer cell migration and invasion through targeting NF1 and mediate MAPK signalling pathway | [157]      |
| miR-4717-5p                 | Malignant lymphoma |                |                   | Induce gemcitabine resistance through targeting ENT2 expression in cancer cells. | [55]       |
| Decreased miR-34a           | Oral squamous cell carcinoma |                |                   | Promote cancer cell proliferation and metastasis through AKT/GSK-3β/β-catenin signalling. miR-34a can target AXL in cancer cells. | [161]      |
| miR-382-5p                  | Oral squamous cell carcinoma |                |                   | Promote cancer cell migration and invasion. miR-382-5p contributes to EV-mediated cancer progression. | [160]      |
| miR-1228                    | Osteosarcoma |                |                   | Promote cancer migration and invasion through targeting SCAI. | [162]      |
| miR-21 isomiR               | Ovarian cancer |                |                   | Confer the chemo-resistance through targeting APAF1 | [163]      |
| miR-98-5p                   | Ovarian cancer |                |                   | Promote cisplatin resistance via targeting CDKN1A. | [164]      |
| miR-106b                    | Pancreatic cancer |                |                   | Gemcitabine induce miR-106a in CAFs and their EVs. CAF-derived miR-106a can promote cancer cell proliferation. | [165]      |
| miR-331-3p                  | Pancreatic cancer |                |                   | Promote cancer progression via targeting SCARA5 expression in PDAC cells. | [191]      |
| miR-92a-3p, miR-181a-5p, miR-222-3p, miR-221-3p, miR-21-5p | Pancreatic cancer |                |                   | CAFs might transfer miRNAs in PDAC cells via EVs and promote gemcitabine resistance. miR-92a-3p could target PTEN expression in PDAC cells. | [190]      |
| miR-1290                    | Prostate cancer |                |                   | Promote EMT and metastasis via targeting GSK3β expression in cancer cell. | [197]      |
| miR-146a-5p                 | Prostate cancer |                |                   | Promote cancer metastasis. Treatment of Dihydrotestosterone (DHT) decreases miR-146a-5p in CAF-derived EVs and attenuate cancer promoting function. | [186]      |
| miR-409                     | Prostate cancer |                |                   | Promote epithelial-mesenchymal transition through repression of tumor suppressor genes such as Ras suppressor 1 and stromal antigen 2 | [166]      |
| miR-224-5p                  | Renal cell carcinoma |                |                   | Contribute to cancer progression. | [167]      |
Table 2 (continued)

| Contents of CAF-derived EVs | Tumour type             | EV donor (From) | EV recipient (To) | Functions of CAF-derived EVs on cancer progression                                                                 | References |
|-----------------------------|-------------------------|----------------|------------------|----------------------------------------------------------------------------------------------------------------------|------------|
| Metabolites                 |                         |                |                  |                                                                                                                      |            |
| mitochondrial DNA (mtDNA)   | Breast cancer           | From CAFs      | To Cancer cells  | Promote estrogen receptor-independent oxidative phosphorylation restore in cancer-stem like cells and increase self-renewal capacity in these cells. | [168]      |
| Metabolites including amino acids and lipids | Prostate cancer |                |                  | Affect the metabolic properties in prostate cancer cells                                                           | [60]       |
| Others                      |                         |                |                  |                                                                                                                      |            |
| RN7SL1                      | Breast cancer           | From CAFs      | To Cancer cells  | Acting as damage-associated molecular patterns (DAMPs) and activating RIG-I in the recipient cancer cells           | [54]       |
| Protein binding, serine-type endopeptidase activity, signalling receptor and protein kinase binding-related molecules | Oral squamous cell carcinoma |                |                  | CAF-derived EVs promote cancer invasion and apoptosis.                                                              | [169]      |
| miR-146a and Snail mRNA     | Pancreatic cancer       |                |                  | Gemcitabine induce the secretion of miR-146 and Snail mRNA via EVs and regulate survival and proliferation in cancer cells | [170]      |
CAF generation and activation. Interestingly, Ma et al. showed the direct transfer of gain-of-function p53 proteins from cancer cells to fibroblasts via EVs. This gain-of-function p53 isoform induced a CAF phenotype in fibroblasts through the Nrf2-dependent pathway [39]. Since Nrf2 is the essential regulator of ECM production and deposition [42], transferring the gain-of-function p53 isoform to CAFs might involve a proinvasive ECM construction. In addition, Vu et al. found that miR-125b in breast cancer cell-derived EVs generates CAFs from resident fibroblasts [43]. Downregulation of TP53INP1 by EV-transferred miR-125b induced a CAF state in fibroblasts to promote tumour growth [43]. Given that aberrant p53 function can confer a CAF phenotype on fibroblasts [38, 39, 44], the expression status of the TP53 gene in both cancer cells and CAFs may reflect the features of CAF subtypes. Recently, Bhome et al. demonstrated that the EMT phenotype of colorectal cancer (CRC) cells influences CAF generation [45] CRC cells with an epithelial phenotype secrete miR-200 family members via EVs to attenuate TGF-β-mediated CAF features by targeting ZEB1 in normal fibroblasts. However, EVs derived from CRC cells with a mesenchymal phenotype contain less miR-200 family, thus allowing TGF-β-mediated CAF feature induction. An aggressive subtype of CRC based on the consensus molecular subtypes (CMSs) is associated with mesenchymal gene signatures. Their study provides
one of the essential clues as to why cancer cells with aggressive phenotypes possess CAF-abundant stroma.

EVs also generate specific CAF subtypes from resident fibroblasts, promoting CAF heterogeneity. Our group reported that highly metastatic gastric cancer (GC) cells secrete EVs and induce the expression of chemokines such as IL-1 and IL-8 in stomach fibroblasts, which have similar properties as iCAFs [46]. Regarding the mechanism, these GC-derived EVs transport miRNAs, including miR-193b, to fibroblasts and induce chemokine expression. On the other hand, these GC cell-derived EVs do not have the capacity to regulate the expression of α-SMA and collagen, which are myCAF features. Notably, compared with GC cells with low metastatic potential, those with high metastatic potential can more strongly induce both α-SMA and chemokine expression in fibroblasts. These data suggest that cancer-derived EVs selectively confer iCAF-like features on fibroblasts. IL-8-expressing CAFs within the tumour stroma are closely associated with poor outcomes in patients with GC. These findings collectively imply that GC generates a protumorigenic microenvironment to support disease progression. Other research groups have also shown that cancer-derived EVs affect CAF heterogeneity [47, 48]. Goulet et al. showed that bladder cancer-derived EVs induce iCAF features in primary bladder fibroblasts [48]. Compared with TGF-β treatment, these cancer-derived EVs have a weaker effect on the induction of α-SMA in fibroblasts [48]. Although these researchers did not clarify the contribution of cancer-derived EVs to iCAFs differentiation, they showed that EV-induced iCAFs express IL-6 and activate the STAT3 signalling pathway that leads to EMT in bladder cancer [48]. Lahav et al. demonstrated that metastatic melanoma cell-derived EVs activate proinflammatory signalling in fibroblasts within metastatic niches [47]. They also found that melanoma cell-derived EVs contain RNAs capable of instigating inflammatory signalling in fibroblasts, such as high-mobility group box 1 (Hmgb1), thymic stromal lymphopoietin (Tslp), and interferon regulatory factor 1 (Irf1) [47]. Interestingly, these EVs cannot induce myCAF features, suggesting that metastatic cancer cell-derived EVs may preferentially encourage iCAF features rather than myCAF features [49]. These findings indicate that EVs deliver messages from cancer cells, instigate various features in CAFs, and affect the feedback from CAFs for cancer progression.

**CAF-derived EVs change the properties of cancer cells during disease progression**

Stromal fibroblasts “educated” by cancer cells also secrete EVs and establish intercellular communication that ultimately benefits cancer progression (Fig. 1 and Table 2). Luga et al. first reported the functional role of CAF-derived EVs in cancer progression. They showed that CD81-positive CAF-derived EVs activate the Wnt-planar cell polarity (PCP) signalling pathway and enhance breast cancer cell motility and metastasis [50]. CD81 on the surface of EVs may support the endocytic trafficking of Wnt11 in cancer cells. This mechanism mediated by CAF-derived EVs activates the Wnt-PCP pathway in cancer cells to drive invasive behaviour [50]. CD81, a tetraspanin family member protein, is a conventional marker of EVs [9]. Other tetraspanin family proteins may also support the internalization of CAF-derived EVs. Miki et al. showed that CAFs secrete CD-9-positive EVs and stimulate diffuse-type GC migration. In addition, they showed that a CD9 neutralizing antibody inhibits EV uptake by GC cell lines [51]. Consistent with this finding, Nigri et al. also demonstrated that CD9 neutralizing antibody impaired CAF-derived ANXA6-positive uptake by PDAC cells [52]. ANXA6 can interact with CD9 in CAFs, suggesting that CD9 might regulate EV-specific ANXA6 shuttling. ANXA6- and CD9-double-positive CAF-derived EVs facilitate p38 MAPK signal activation to enhance migratory ability in PDAC cells. Although these reports did not clarify how the suppression of CD9 expression inhibits EV uptake in cancer cells, they identified CD9 function as a mediator of the internalization of CAF-derived EVs into cancer cells.

CAF-derived EVs support the development of cancer cell therapeutic resistance. Minn’s group reported the precise mechanisms by which breast cancer cells achieve therapeutic resistance through CAF-derived EVs [53, 54]. CAF-derived EVs contain transposable RNAs that stimulate RIG-I recognition to activate STAT1 in cancer cells. Activated STAT1 cooperates with juxtacrine-activated NOTCH3 to mediate NOTCH target gene transcription that supports resistance to chemotherapy and radiation [53]. They also found that NOTCH-MYC signalling induces RN7SL1 expression in CAFs. RN7SL1 generally possesses 5′ppp capping that is regulated by SRP9 and SRP14, which may prevent its recognition by RIG-I. However, NOTCH-MYC signalling in CAFs induces RN7SL1 without 5′ppp capping, which is encapsulated into CAF-derived EVs and acts as a damage-associated molecular pattern (DAMP) to activate RIG-I in recipient cancer cells [54]. Kunou et al. demonstrated the function of CAF-derived EVs in the gemcitabine resistance in malignant lymphoma [55]. These CAF-derived EVs suppress the expression of equilibrative nucleoside transporter 2 (ENT2) in lymphoma cells. They also found that miR-4717-5p is one of the most abundant miRNAs in CAF-derived EVs and directly targets ENT2 expression [55]. In colorectal cancer (CRC), Deng et al. showed that FAP-positive CAFs secrete lncRNAs via EVs [56]. These CAF-derived lncRNAs
promote oxaliplatin resistance in CRC cells in vitro and in vivo by stabilizing human antigen R (HuR) mRNA to increase β-catenin expression. The FAP-positive CAF subset is associated with regulatory T-cell-mediated immunosuppression, which results in poor outcomes in breast cancer patients [57]. Thus, it is possible that the FAP-positive CAF subset also secretes functional EVs to facilitate the malignant behaviour of cancer cells. Indeed, Dou et al. reported the immunomodulatory functions of CAF-derived EVs [58]. Although they did not refer to CAF subsets, they showed that CAF-derived miR-92 directly targets LATS2 expression and induces PD-L1 expression through YAP activation in breast cancer cells [58].

The functional role of CAF subset-derived EVs in cancer progression was recently reported. Gao et al. identified CD63-positive CAF subsets using single-cell analysis of oestrogen receptor α (ERα)-negative tumours in the MMTV-PyMT mouse mammary gland carcinoma model [59]. These CAF subsets secrete miR-22 via EVs to directly suppress the expression of ERα and PTEN in ERα-positive breast cancer cells and organoids, resulting in the induction of tamoxifen resistance. Interestingly, TIMP1, a CD63 ligand, can induce the STAT3 signalling pathway to regulate the expression of miR-22 and CD63 to generate a CD63-positive CAF phenotype. TIMP1 is upregulated in CD63-positive CAFs, suggesting a TIMP1-mediated positive feedback loop in the CD63-positive CAF phenotype. In addition, they showed that SFRS1 mediates miR-22 loading into CD63-positive CAF-derived EVs [59]. Although it is still unclear whether EV components differ among all CAF subsets, these findings indicate that CAF heterogeneity affects EV function in cancer progression.

Cancer-derived EVs reprogram energy metabolism in CAFs, as discussed in the previous section. CAFs also support the metabolic properties of cancer cells [60, 61]. Zhao et al. showed that CAF-derived EVs contain intact metabolites, such as amino acids, and change the metabolic properties of prostate cancer cells [60, 61]. Oxidative phosphorylation is inhibited in the presence of CAF-derived EVs. In contrast, glycolysis and lactate levels in prostate cancer cell lines are increased by these CAF-derived EVs. In addition to the direct transfer of metabolites via EVs, Li et al. also showed that the IncRNA SNHG3 affects the metabolic reprogramming of breast cancer cells. SNHG3 in EVs acts as a molecular sponge of miR-330-5p, resulting in increased lactate production in breast cancer cells [62]. Breast cancer-derived EVs transfer miR-122 and modify glucose consumption by fibroblasts at metastatic sites by targeting pyruvate kinases [63]. Moreover, metabolic dysregulation of CAFs may alter immunoregulation through IL-6 production [36].

Collectively, these findings imply that communication networks involving EVs contribute to cancer survival in environments with limited oxygen and nutrient supplies.

**Perspectives on the therapeutic and diagnostic application of CAF-derived EVs**

As described above, EV-mediated interactions between cancer cells and CAFs have been implicated in several malignant behaviours of cancer cells. Therefore, targeting EVs and CAFs is being explored as a fascinating strategy for cancer therapy. Kong et al. suggested that the inhibition of vitamin D receptor (VDR) signalling could target miR-10 secretion via EVs from CAFs and inhibit its cancer-promoting functions in PDAC [64]. This study was motivated by the two reports demonstrating that VDR signalling reprograms CAFs, thus diminishing their cancer-promoting role in PDAC, and is associated with better clinical outcomes in CRC [65, 66]. The inhibitory effects of two compounds on the interplay between cancer cells and CAFs have also been demonstrated. Lee et al. showed the impact of the multitarget small drug HNC0014 on the function of cancer spheroid-derived EVs. HNC0014 inhibits CAF generation by these EVs and may contribute to the antitumour immune response [67]. Chen et al. utilized ovatodiolide (OV), the bioactive component of *Anisomeles indica*, to suppress CAF generation and tumour sphere formation induced by cancer-derived EVs [68]. Interestingly, proton-pump inhibitors (PPIs), which are used to eradicate the oncogenic pathogen *Heliobacter pylori*, may also inhibit CAF generation [69].

Some studies have identified the molecules specific to CAF-derived EVs and these molecules have been proposed as diagnostic biomarkers for cancer. Ganig et al. performed proteome analysis of EVs derived from CAFs and normal fibroblasts and identified 11 proteins with differential abundance in CAF-derived EVs [70]. Among these candidate proteins, QSOX1 was selected for further study and was found to be decreased in CAF-derived EVs compared with normal fibroblast-derived EVs. The abundance of QSOX1 in plasma samples was reduced in CRC patients compared to healthy donors and patients with benign disease [70]. Although this study used small cohorts to investigate QSOX1 in EVs, the findings suggest the utility of CAF-derived EVs in cancer diagnosis. The secretome of fibroblasts influenced by cancer-derived EVs has also been investigated as a biomarker for lung cancer detection. Zhang et al. compared the secretome profile of lung cancer-derived EV treated and untreated MRC5 fibroblasts to find candidates for a diagnostic marker [71]. Based on the multiple datasets comprising 1897 patient samples, they showed that the gene expression signatures of five candidates are independent.
prognostic factors for identifying patients who may require adjuvant therapy.

There remain challenges in the clinical application of EVs because of their diversity and the difficulty in selectively targeting cancer-associated EVs [8]. However, further investigations into targeting intercellular communication via EVs will provide several avenues for cancer therapy and diagnosis.

Conclusion

The precise mechanisms of intercellular communication between cancer cells and CAFs remain obscure because diverse pathways modulate multiple EV components and non-EV factors, such as growth factors, cytokines and chemokines. In addition, CAFs are surprisingly heterogeneous, which is the major obstacle to understanding their biology and developing related therapeutics. However, as described above, remarkable progress in EV research has led to the elucidation of the novel mechanism underlying the intrinsic cancer cell–stromal cell interplay during cancer initiation and progression. EVs derived from cancer cells and CAFs have impressively diverse functions that contribute to tumour progression. Cancer cells secrete EVs and thus dictate specific properties in CAFs. Against such “education” by cancer cells, CAFs “respond” via EVs to suppress cancer initiation and progression. Understanding the precise mechanisms of EVs in cancer cell–CAF interactions may provide breakthroughs in the development of diagnostic and prognostic tools and therapeutic strategies for cancer.

Abbreviations

CAFs: Cancer-associated fibroblasts; EVs: Extracellular vesicles; miRNAs: MicroRNAs; TME: Tumour microenvironment; MVBs: Multivesicular bodies; ESCRT: Endosomal sorting complex required for transport; BM-MSCs: Bone marrow-derived mesenchymal stem cells; α-SMA: Alpha-smooth muscle actin; EMT: Epithelial–mesenchymal transition; TGF-β: Transforming growth factor-β; CXCL12: CXCR4 chemokine ligand 12; LIF: Leukaemia inhibitory factor; apCAFs: Antigen-presenting CAFs; ECM: Extracellular matrix; FGF2: Fibroblast growth factor 2; ITGB4: Integrin beta 4; BNIP3L: BCL2-interacting protein 3 like; B4GALT3: β-1,4-Galactosyltransferase III; IncRNAs: Long non-coding RNAs; PDAC: Pancreatic ductal adenocarcinoma; iCAFs: Inflammatory CAFs; myCAFs: Myofibroblastic CAFs; GC: Gastric cancer; Hmgb1: High-mobility group box 1; Tspo: Thymic stromal lymphopoietin; Irf1: Interferon regulatory factor 1; Pcp: Planar cell polarity; Dnap: Damage-associated molecular pattern; Ent2: Equilibrative nucleoside transporter 2; CrC: Colorectal cancer; HuR: Human antigen R; Erα: Oestrogen receptor α; VDR: Vitamin D receptor.

Acknowledgements

This work was supported by JSPS KAKENHI Grant Number 22K15567 and Project for Cancer Research and Therapeutic Evolution (P-PROMOTE) Grant number: 22ama221405h0001 from the Japan Agency for Medical Research and Development (AMED).

Author contributions

YN and YY made the literature analysis and wrote, and discussed and revised the manuscript of this review. YY and TO analyzed and corrected the manuscript. YN and YY, made the literature analysis and revised the design of the image. All authors read and approved the final manuscript.

Funding

This work was supported by JSPS KAKENHI Grant Number 22K15567 and Project for Cancer Research and Therapeutic Evolution (P-PROMOTE) Grant Number: 22ama221405h0001 from the Japan Agency for Medical Research and Development (AMED).

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1. Department of Bioregulation, Institute for Advanced Medical Sciences, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-Ku, Tokyo 113-8602, Japan.
2. Department of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University, 6-7-1, Nishishinjuku, Shinjuku-Ku, Tokyo 160-0023, Japan.

Received: 7 June 2022   Accepted: 20 October 2022
Published online: 24 November 2022

References

1. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239–52.
2. Sahai E, Attisatoa I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174–86.
3. Belli C, Trapani D, Viale G, D’Amico P, Duso BA, Dellà Vigna P, Orsi F, Curigliano G. Targeting the microenvironment in solid tumors. Cancer Treat Rev. 2018;65:22–32.
4. Kogure A, Ochiya T. Extracellular vesicles in cancer metastasis: potential as therapeutic targets and materials. Int J Mol Sci. 2020;21(12):4463.
5. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of miRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–9.
6. Yokoi A, Ochiya T. Exosomes and extracellular vesicles: rethinking the essential values in cancer biology. Semin Cancer Biol. 2021;74:79–91.
7. Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesci Mark M, Molina H, Kohsaka S, Di Giannattale A, Ceder S, et al. Tumour exosome exosomes determine organotrophic metastasis. Nature. 2015;527(7578):526–35.
8. Urabe F, Kosaka N, Ito K, Kimura T, Egawa S, Ochiya T. Extracellular vesicles as biomarkers and therapeutic targets for cancer. Am J Physiol Cell Physiol. 2020;318(1):C29-c39.
9. Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arbab T, Archer F, Atkin-Smith GK, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750.
10. Lötvall J, Hill AF, Hochberg F, Buzás EI, Di Vizio D, Gardiner C, Gho YS, Kurochkin IV, Mathivanan S, Quesenberry P, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles. 2014;3:26913.
11. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–83.
12. Muralidharan-Chari V, Clancy JW, Sedgwick A, D’Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci. 2010;123( Pt 10):1603–11.

13. Akers JC, Gonda D, Kim R, Carter BS, Chen CC. Biogenesis of extracellular vesicles (EVs): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol. 2013;113(1):1–11.

14. Elmore S. Apoptosis: a review of programmes cell death. Toxicol Pathol. 2007;35(4):495–516.

15. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392–401.

16. Bartoschek M, Oskolkov N, Bocci M, Lovrot J, Larsson C, Sommarin M, Madsen CD, Lindgren D, Pezar G, Karlsson G, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun. 2018;9(1):1510.

17. Lambrechts D, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O, Bassez A, Decaluwe H, Pircher A, Van den Eynde K, et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med. 2018;24(8):1277–89.

18. Sugimoto H, Munde1 TM, Kieran MW, Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther. 2006;5(12):1640–6.

19. Raz Y, Cohen N, Shani O, Bell RE, Novitskiy SV, Abramovitz L, Levy C, Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;215(12):3075–93.

20. Ohlund D, Handly-Santana A, Biffi G, Elayda E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579–96.

21. Biffi G, Oni TE, Spielman H, Hao Y, Elayda E, Park Y, Preall J, Tuveson DA. IL-1β-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019;9(2):282–301.

22. Massagué J. TGFβ in cancer. Cell. 2008;134(2):215–30.

23. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Su S, Chen J, Yao H, Liu J, Yu S, Lao L, Wang M, Luo M, Xing Y, Chen F, Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor et al. CD10(+) Cancer-associated fibroblasts promote cancer progression. J Cell Sci. 2010;123(Pt 10):1603–11.

24. Cossarizza A, Decaluwé H, Pircher A, Van den Eynde K, et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med. 2018;24(8):1277–89.

25. Webber J, Steadman R, Mason MD, Tabi Z, Clayton A. Cancer exosomes: triggered fibroblast to myofibroblast differentiation. Cancer Res. 2010;70(23):9621–30.

26. Webber JP, Spary LK, Sanders AJ, Chowdhury R, Jiang W, Steadman R, Wymant J, Jones AT, Kynaston H, Mason MD, et al. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene. 2015;34(3):290–302.

27. Huang Q, Hsuueh CY, Shen YJ, Guo Y, Huang JM, Zhang YF, Li JY, Gong HL, Zhou L. Small extracellular vesicle-packaged TGFβ1 promotes the reprogramming of normal fibroblasts into cancer-associated fibroblasts by regulating fibronectin in head and neck squamous cell carcinoma. Cancer Lett. 2021;517:1–13.

28. Sung JS, Kang CW, Wang S, Jiang Y, Chae YC, Kim BG, Cho NH. iTGB4-mediated metabolic reprogramming of cancer-associated fibroblasts. Oncogene. 2020;39(3):664–76.

29. Yan W, Wu X, Zhou W, Fong MY, Cao M, Liu J, Liu X, Chen CH, Fadare O, Pizzo DP, et al. Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol. 2018;20(5):597–609.

30. Sanford-Crane H, Abrego J, Sherman MH. Fibroblasts as modulators of local and systemic cancer metabolism. Cancers (Basel). 2019;11(5):619.

31. Valencia T, Kim JY, Abu-Baker S, Moscat-Pardos J, Ahn CS, Reina-Casal J, Campos M, Duran A, Castillo EA, Metallo CM, Diaz-Merco MT, et al. Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell. 2014;26(1):121–35.

32. Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin Cancer Biol. 2014;25:47–60.

33. Novo D, Heath N, Mitchell L, Caliguri G, MacFarlane A, Reijmer D, Charlton L, Knight J, Calka M, McGhee E, et al. Mutant p53 releases pro-inflammatory niches by inducing exosome podocalyxin levels. Nat Commun. 2018;9(1):5069.

34. Ma S, McGuire MH, Mangala LS, Lee S, Stur E, Hu W, Baytakar E, Willar-Prados A, Ivan C, Wu SY, et al. Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. Cell Rep. 2021;34(6):108726.

35. Tape CJ, Ling S, Dimitriadi M, McMahon KM, Worboys JD, Leong HS, Bhome R, Emaduddin M, James V, House LM, Thirdborough SM, Melone M, Tulkens J, Primrose JN, Thomas GJ, De Wever O, et al. Epithelial to mesenchymal transition influences fibroblast phenotype in colorectal cancer by altering miR-200 levels in extracellular vesicles. J Extracell Vesicles. 2022;11(5):e12226.

36. Naito Y, Yamamoto Y, Sakamoto N, Shimomura J, Kogure A, Kumazaki N, Fujinaga T, Hiyama S, Kodama T, et al. Exosomal microRNAs derived from colon cancer cells promote tumor progression by suppressing fibroblast TP53 expression. Cancer Sci. 2019;110(8):2396–407.

37. Bhome R, Emaduddin M, James V, House LM, Thirdborough SM, Melone M, Tulkens J, Primrose JN, Thomas GJ, De Wever O, et al. Epithelial to mesenchymal transition influences fibroblast phenotype in colorectal cancer by altering miR-200 levels in extracellular vesicles. J Extracell Vesicles. 2022;11(5):e12226.

38. Fang T, Lu H, Lv G, Li T, Wang C, Han Q, Yu L, Su B, Guo L, Huang S, et al. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat Commun. 2018;9(1):191.
50. Luga V, Zhang L, Vilaroa-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, Buchanan M, Hosein AN, Basik M, Wana JL. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012;151(7):1542–56.

51. Miki Y, Yashiro M, Okuno T, Kiyama K, Masuda G, Hirakawa K, Ohisa M. CD9-positive exosomes from cancer-associated fibroblasts stimulate the migration ability of scarrrhous-type gastric cancer cells. Br J Cancer. 2018;118(6):867–77.

52. Nigri J, Lea J, Tubiana SS, Finetti P, Guillaumond F, Martinez S, Lec S, Iovanna JL, Audebert S, Camoni L, et al. CD9 mediates the uptake of extracellular vesicles from cancer-associated fibroblasts that promote pancreatic cancer cell aggressiveness. Sci Signal. 2022;15(745):eaqb8191.

53. Boelens MC, Wu TJ, Nabet BY, Xu B, Qu Y, Yoon T, Azzam DJ, Twymann-Saint Victor C, Wiemann BZ, Ishwaran H, et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell. 2014;159(3):499–513.

54. Nabet BY, Qu Y, Shabason JE, Wu TJ, Yoon T, Kim BC, Benci JL, De Michele AM, Tchou J, Marchetigiano J, et al. Exosome RNA upshuffling couples stromal activation to pattern recognition receptor signaling in cancer. Cell. 2017;170(2):352–366.e313.

55. Kunou S, Shimada K, Takai M, Sakamoto A, Aoki T, Hikita T, Kaga Y, Iwamoto E, Sanada M, Shimada S, et al. Exosomes secreted from cancer-associated fibroblasts elicit anti-angiogenic drug resistance through modulation of its transporter in malignant lymphoma. Oncogene. 2021;40(23):3989–4003.

56. Deng X, Ruan H, Zhang X, Xu X, Zhu Y, Peng H, Zhang X, Kong F, Guan M. Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells. Int J Cancer. 2020;146(6):1700–16.

57. Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, Sir-Dou D, Ren X, Han M, Xu X, Ge X, Gu Y, Wang X. Cancer-associated fibroblasts. Sci Rep. 2020;10(1):8686.

58. Sherman MH, Yu RT, Engle DD, Dong N, Atkins AR, Trinc H, Collison EA, Connor F, Van Dyke T, Kodov S, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatic cancers and enhances pancreatic cancer therapy. Cell. 2014;159(1):80–93.

59. Lee AH, Ghosh D, Quach N, Schroeder D, Dawson MR. Ovarian cancer exosomes trigger differential biophysical response in tumor-derived fibroblasts. Sci Rep. 2020;10(1):8686.

60. Chen JH, Wu ATH, Bamodu OA, Yadav VK, Chao TY, Tseng YM, Mkhophadwyq D, Hsiao M, Lee JC. Ovatodiolide suppresses oral cancer malignancy by down-regulating exosomal Mir-21/STAT3/b-catenin cargo and preventing oncogenic transformation of normal gingival fibroblasts. Cancers (Basel). 2019;11(12):156.

61. Huang J, Ding Z, Luo Q, Xu W. Cancer cell-derived exosomes promote chemo-resistance of colorectal cancer cells through PKM2. Oncotarget. 2018;9(50):29453–67.

62. Gu J, Li X, Zhao L, Yang Y, Xue C, Gao Y, Li J, Han Q, Sun Z, Bai C, et al. CD63+ cancer-associated fibroblasts confer tamoxifen resistance to breast cancer cells. Oncotarget. 2016;7(35):40229–40.

63. Li K, Liu T, Chen J, Ni H, Li W. Survivin in breast cancer-derived exosomes activates fibroblasts by up-regulating SOD1, whose feedback promotes cancer proliferation and metastasis. J Biol Chem. 2020;295(40):13737–52.

64. Liang Li, Yang Y, Wei WF, Wu XG, Yan RM, Zhou CF, Chen XJ, Wu S, Wang F, Lan FS. Tumor-secreted exosomal Wnt2B activates fibroblasts to promote cervical cancer progression. Oncogenesis. 2021;10(3):30.

65. Wu X, Zhou Z, Xu S, Liao C, Chen X, Li B, Peng J, Li D, Yang L. Extracellular vesicle packaged LMP1-activated fibroblasts promote tumor progression via autophagy and stroma-tumor metabolism coupling. Cancer Lett. 2020;478:93–106.

66. Gu J, Li X, Zhao L, Yang Y, Xue C, Gao Y, Li J, Han Q, Sun Z, Bai C, et al. The role of PKM2 nuclear translocation in the constant activation of the NF-κB signaling pathway in cancer-associated fibroblasts. Cell Death Dis. 2021;12(4):291.

67. Wang D, Zhao C, Xu F, Zhang A, Jin M, Zhang K, Liu L, Hua Q, Zhao J, Liu J, et al. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. Theranostics. 2021;11(6):2860–75.

68. Huang J, Ding Z, Luo Q, Xu W. Cancer cell-derived exosomes promote cell proliferation and inhibit cell apoptosis of both normal lung fibroblasts and non-small cell lung cancer cells through delivering alpha-smooth muscle actin. Am J Transl Res. 2019;11(3):1711–23.

69. Wei M, Yang T, Chen X, Wu Y, Deng X, He W, Yang J, Wang Z. Malignant ascites-derived exosomes promotes proliferation and induce carcinoma-associated fibroblasts transition in peritoneal mesothelial cells. Oncotarget. 2017;8(26):42262–71.

70. Zhang Y, Liu Z, Yang X, Lu W, Chen Y, Lin J, Sun Y, Yun JP, H9K27 acetylation activated-COL6A1 promotes osteosarcoma lung metastasis by repressing STAT1 and activating pulmonary cancer-associated fibroblasts. Theranostics. 2021;11(3):1473–92.

71. Novicio N, Belvedere R, Pessolano E, Tosco A, Porta A, Perretti M, Campiglia F, Filippelli A, Petrella A. Annexin A1 released in extracellular vesicles by pancreatic cancer cells activates components of the tumor microenvironment, through interaction with the formyl-peptide receptors. Cells. 2020;9(12):2719.

72. Zhang YF, Zhou YZ, Zhang B, Huang SF, Li PP, He XM, Cao GD, Kang MX, Dong X, Wu YL. Pancreatic cancer-derived exosomes promoted pancreatic stellate cells recruitment by pancreatic cancer. J Cancer. 2019;10(18):4397–407.
84. McAtee CO, Booth C, Blowsky C, Zhao L, Payne J, Fangman T, Caplan S, Henry MD, Simpson MA. Prostate tumor cell exosomes containing hyaluronidase Hyal1 stimulate prostate stromal cell motility by engagement of FAK-mediated integrin signaling. Matrix Biol. 2019;78–79:165–79.

85. Overmiller AM, Perluissi JA, Wermuth PJ, Sauma S, Martínez-Outschoorn U, Tuluc M, Luginbuhl A, Curry J, Harshyne LA, Wahl JK 3rd, et al. Desmoglein 2 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes. Faseb J. 2017;31(8):3412–24.

86. Ren Z, Lv M, Yu Q, Bao J, Lou K, Li X. MicroRNA-370-3p shuttled by breast cancer cell-derived extracellular vesicles induces fibroblast activation through the CYLD/NF-κB axis to promote breast cancer progression. Faseb J. 2021;35(3):e21383.

87. Qin X, Lu M, Li G, Zhou Y, Liu Z. Downregulation of tumor-derived exosomal miR-34c induces cancer-associated fibroblast activation to promote cholangiocarcinoma progression. Cancer Cell Int. 2021;21(1):373.

88. Yang Y, Li J, Geng Y. Exosomes derived from chronic lymphocytic leukemia cells transfer miR-146a to induce the transition of mesenchymal stromal cells into cancer-associated fibroblasts. J Biochem. 2020;168(5):491–8.

89. Wang J, Liu Y, Li Y, Zheng X, Gan J, Wan Z, Zhang J, Liu Y, Wang Y, Hu W, et al. Exosomal miR-10a derived from colorectal cancer cells suppresses migration of human lung fibroblasts, and expression of IL-6, IL-8 and IL-1β. Mol Med Rep. 2021;23(1):373.

90. Wang J, Guan X, Zhang Y, Ge S, Zhang L, Li H, Wang X, Liu R, Ning T, Deng T, et al. Exosomal miR-27a derived from gastric cancer cells regulates the transformation of fibroblasts into cancer-associated fibroblasts. Cell Physiol Biochem. 2018;49(3):869–83.

91. Zhu G, Gao B, Liang X, Li L, Hao Y, Meng W, He C, Wang L, Li L. Small extracellular vesicles containing miR-192/215 mediate hypoxia-induced cancer-associated fibroblast development in head and neck squamous cell carcinoma. Cancer Lett. 2021;506:11–22.

92. Zhou Y, Ren H, Dai B, Li J, Shang L, Huang J, Shi X. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J Exp Clin Cancer Res. 2018;37(1):324.

93. Wei H, Wang J, Xu Z, Li W, Wu X, Zhuo C, Lu Y, Long X, Tang Q, Pu J. Hepatoma cell-derived extracellular vesicles promote liver cancer metastasis by inducing the differentiation of bone marrow stem cells through microRNA-181d-5p and the FAK/ Src pathway. Front Cell Dev Biol. 2021;9:607001.

94. Du C, Duan X, Yao X, Wan J, Cheng Y, Wang Y, Yan Y, Zhang L, Zhu L, Ni C, et al. Tumour-derived exosomal miR-3473b promotes lung tumour cell intrapulmonary colonization by activating the nuclear factor-κB of local fibroblasts. J Cell Mol Med. 2020;24(14):7802–13.

95. Fan J, Xu G, Chang Z, Zhu L, Yao J. miR-210 transferred by lung cancer exosomes contributes to cardiac fibroblast-led cancer invasion. Proteomics. 2020;20(14):e2000016.

96. Huang YJ, Huang TH, Yadav VK, Sumitra MR, Tengz DT, Wei PL, Shih JY, Wu AT. Preclinical investigation of ovotaxodiol as a potential inhibitor of colon cancer stem cells via downregulating sphere-derived exosomal β-catenin/STAT3/miR-1246 cargos. Am J Cancer Res. 2020;10(8):3237–54.

97. Zhang D, Li D, Shen L, Hu D, Tang B, Guo W, Wang Z, Zhang Z, Wei G, He D. Exosomes derived from Piwi12-induced cancer stem cells transform fibroblasts into cancer-associated fibroblasts. Oncol Rep. 2020;43(4):1125–32.

98. Ning X, Zhang H, Wang C, Song X. Exosomes released by gastric cancer cells induce transition of pericytes into cancer-associated fibroblasts. Med Sci Monit. 2018;24:2350–9.

99. Gu J, Qian H, Shen L, Zhang X, Zhu W, Huang L, Yan Y, Mao F, Zhao C, Shi Y, et al. Gastric cancer exosomes trigger differentiation of umbilical cord derived mesenchymal stem cells to carcinoma-associated fibroblasts through TGF-β/Smad pathway. PLoS ONE. 2012;7(12):e52465.

100. Goliwas KF, Ashraf HM, Wood AM, Wang Y, Hough KP, Bodduluri S, Athar M, Berry J, Ponnazhagan S, Thannickal VJ, et al. Extracellular vesicle-mediated tumor-stromal crosstalk within an engineered lung cancer model. Front Oncol. 2021;11:654922.

101. Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S, Mulholland D, Rotin M, Hager MH, Insabato L, et al. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol. 2012;181(5):1573–84.

102. Xu Z, Zheng X, Zheng J. Tumor-derived exosomes educate fibroblasts to promote salivary adenoid cystic carcinoma metastasis via NF-κB/NTRK1 pathway. Oncol Lett. 2019;18(22):3085–94.

103. Shimoda M, Principe S, Peppelenbosch M, Fuhler G, Consonni SR, Ferreira-Halder T, Ødum N, Schrama D, Schadendorf D, et al. Merkel cell carcinoma-secreted miR-3473b promotes lung tumour cell progression through microRNA-181d-5p and the FAK/ Src pathway. Front Cell Dev Biol. 2021;9:652322.

104. Pang W, Su J, Wang Y, Feng H, Dai X, Yuan Y, Chen X, Yao W. Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancer-associated fibroblasts. Cancer Sci. 2015;106(10):1362–9.

105. Ghayad SE, Rammal G, Ghamlouch F, Basma H, Nasr R, Diab-Assaf M, Chelala C, Saab R. Exosomes derived from embryonal and alveolar rhabdomyosarcoma carry differential miRNA cargo and promote invasion of recipient fibroblasts. Sci Rep. 2016;6:37088.

106. Clerici SP, Peppelenbosch M, Fuhler G, Consonni SR, Ferreira-Halder T, Ødum N, Schrama D, Schadendorf D, et al. Merkel cell carcinoma-secreted miR-3473b promotes lung tumour cell progression through the CYLD/NF-κB axis to promote breast cancer progression. Faseb J. 2021;35(3):e21383.
120. Uchihara T, Miyake K, Yonemura A, Komohara Y, Itoyama R, Koiwa M, Naito et al. Cancer Cell International (2022) 22:367.

121. Grunberg N, Pevsner-Fischer M, Goshen-Lago T, Diment J, Steyn Y, Lavon Li W, Zhang X, Wang J, Li M, Cao C, Tan J, Ma D, Gao Q. TGFβ1 in Toti A, Santi A, Pardella E, Nesi I, Tomasini R, Mello T, Paoli P, Caselli Y. J, Li M, Cao LM, Gu QH, Deng PB, Tan Y, Hu CP. Snail1-dependent Zhang Y, Luo G, You S, Zhang L, Liang C, Chen X. Exosomal LINC00355 derived from cancer-associated fibroblasts promotes bladder cancer cell proliferation and invasion by regulating miR-15a-5p/HMGA2 axis. Acta Biochim Biophys Sin (Shanghai). 2021;53(6):673–82.

124. You J, Li M, Cao LM, Gu QH, Deng PB, Tan Y, Hu CP. Snail1-dependent Zhang Y, Luo G, You S, Zhang L, Liang C, Chen X. Exosomal LINC00355 derived from cancer-associated fibroblasts promotes breast cancer cell proliferation and metastasis through targeting USP28. Theranostics. 2021;11(8):3932–47.

127. Chen B, Sang Y, Song X, Zhang D, Wang L, Zhao W, Liang Y, Zhang N, Yang Q. Exosomal miR-300a-5p derived from cancer-associated fibroblasts promotes breast cancer cell proliferation and metastasis in lung cancer cells via exosomes. JOM. 2019;11(28):581–90.

128. Liu Y, Hua F, Zhan Y, Yang Y, Xie J, Cheng Y, Li F. Carcinoma associated fibroblasts-derived exosomes mediate transfer of LINC00355 regulates bladder cancer cell proliferation and invasion. Cell Biochem Funct. 2020;38(3):257–65.

129. Chen B, Sang Y, Song X, Zhang D, Wang L, Wang D, Li F. MiR-3613-3p from carcinoma-associated fibroblasts exosomes promotes breast cancer cell proliferation and metastasis by regulating SOCS2 expression. IUBMB Life. 2020;72(8):1705–14.

130. Wu HJ, Hao M, Yeo SK, Guan JL. FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication. Oncogene. 2020;39(12):2539–49.

131. Wang H, Wei H, Wang J, Li L, Chen A, Li Z. MicroRNA-181d-5p-containing exosomes derived from CAFs promote EMT by regulating CD2X/POKX5 in breast cancer. Mol Ther Nucleic Acids. 2020;19:654–67.

132. Kim JE, Kim BG, Ji Y, Kang S, Lee JH, Cho NH. The stromal loss of miR-4516 promotes the FOsL1-dependent proliferation and malignancy of triple negative breast cancer. Cancer Lett. 2020;469:256–65.

133. Liu Y, Hua F, Zhan Y, Yang Y, Xie J, Cheng Y, Li F. Carcinoma associated fibroblasts small extracellular vesicles with low miR-7641 promotes breast cancer cell proliferation and metastasis by regulating exosomal miR-210. Aging (Albany NY). 2020;12(9):8549–64.

134. Zhang H, Deng T, Liu R, Ting T, Yang H, Liu D, Zhang Q, Lin D, Ge S, Bai M, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020;19(1):43.

135. Xu G, Zhang B, Ye J, Cao S, Shi J, Zhao Y, Yang W, Sang Y, Jiao Y, Gao W, et al. Exosomal miR-139 in cancer-associated fibroblasts inhibits gastric cancer cell proliferation by repressing MMP11 expression. Int J Biol Sci. 2019;15(11):2320–9.

136. Shi H, Huang L, Qin G, Yang Q, Ren F, Shen C, Wang S, Liu S, Jian L, Wang D, et al. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma. Cancer Lett. 2021;518:35–48.

137. Shi L, Wang Z, Geng X, Zhang Y, Xue Z. Exosomal miR-34a from cancer-associated fibroblasts inhibits growth and invasion of gastric cancer cells in vitro and in vivo. Aging (Albany NY). 2020;12(9):8549–64.

138. Zhang H, Deng T, Liu R, Ting T, Yang H, Liu D, Zhang Q, Lin D, Ge S, Bai M, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020;19(1):43.

139. Wang X, Qin X, Yan M, Shi J, Xu Q, Li X, Yang W, Zhang J, Chen J, Wang C. Loss of exosomal miR-3188 in cancer-associated fibroblasts contributes to HNC progression. J Exp Clin Cancer Res. 2019;38(1):151.

140. Qin X, Guo H, Wang X, Zhu X, Yan M, Wang X, Xu Q, Shi J, Lu E, Chen W, et al. Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDK10/10 and INGS. Genome Biol. 2019;20(1):12.

141. Yugawa K, Yoshizumi T, Mamo Y, Ichh S, Harada N, Ikegami T, Koshishi K, Oda Y, Mori M. Cancer-associated fibroblasts promote hepato cellular carcinoma progression through downregulation of exosomal miR-150-3p. Eur J Surg Oncol. 2021;47(2):384–93.

142. Liu X, Wang H, Yang M, Hou Y, Chen Y, pie B. Exosomal miR-29b from cancer-associated fibroblasts inhibits the migration and invasion of hepatocellular carcinoma cells. Transl Cancer Res. 2020;9(4):2576–87.

143. Zhang Z, Li X, Sun W, Yue S, Yang J, Li M, Bai B, Wang J, Yang X, Pu M, et al. Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to RCC proliferation and metastasis. Cancer Lett. 2017;379:33–42.

144. Yang F, Yan Y, Yang H, Wang X, Wang M, Yang Z, Liu B, Ye L, et al. MiR-210 in exosomes derived from CAFs promotes non-small cell lung cancer migration and invasion through PTEN/PI3K/AKT pathway. Cell Signal. 2020;73:109675.

145. Guo L, Li B, Yang J, Shen J, Ji J, Miao M. Fibroblast-derived exosomal microRNA-369 potentiates migration and invasion of lung squamous cell carcinoma. Aging (Albany NY). 2020;12(9):8549–64.
cell carcinoma cells via NF-κ-mediated MAPK signaling pathway. Int J Mol Med. 2020;46(2):595–608.

158. Zhang T, Zhang P, Li HX. CAFs-derived exosomal miRNA-130a confers cisplatin resistance of NSCLC cells through PUM2-dependent packaging. Int J Nanomedicine. 2021;16:561–77.

159. Wang H, Huang H, Wang L, Liu Y, Wang M, Zhao S, Lu G, Kang X. Cancer-associated fibroblasts secreted miR-103a-3p suppresses apoptosis and promotes cisplatin resistance in non-small cell lung cancer. Aging (Albany NY). 2021;13(10):14456–68.

160. Sun LF, Xu K, Cui J, Yuan DY, Zou B, Li J, Liu JL, Li KY, Meng Z, Zhang B. Cancer-associated fibroblast-derived exosomal miR-382-Sp promotes the migration and invasion of oral squamous cell carcinoma. Oncol Rep. 2019;42(4):1139–28.

161. Li YY, Tao YW, Gao S, Li P, Zhang JM, Zhang SE, Liang J, Zhang Y. Cancer Wang JW, Wu XF, Gu XJ, Jiang XH. Exosomal miR-1228 from cancer-associated fibroblasts promote cell migration and invasion of osteosarcoma by directly targeting SCEL. Oncol Res. 2019;27(9):979–86.

163. Au Yeung CL, Co NN, Tsuruga T, Yeung TL, Kwan SY, Leung CS, Li Y, Lu K, Josson S, Gururajan M, Sung SY, Hu P, Shao C, Zhau HE, Liu C, Lichter P, Sansone P, Savini C, Kurelac I, Chang Q, Amato LB, Strillacci A, Stepanova A, Dourado MR, Korvala J, Åström P, De Oliveira CE, Cervigne NK, Mofatto P, Scognamiglio I, Cocca L, Puoti I, Palma F, Ingenito F, Quintavalle C, Feng T, Fang F, Zhang C, Li T, He J, Shen Y, Yu H, Liu X. Fluid shear stress-induced exosomes from cervical cancer cells promote migration and invasion of oral squamous cell carcinoma. J Extracell Vesicles. 2019;8(1):157825.

166. Richards KE, Xiao W, Hill R, On Behalf Of The Usc Pancreas Research T. Sulfonylurea receptor 1-expressing cancer cells induce the migration and invasion of oral squamous cell carcinoma. J Extracell Vesicles. 2019;8(1):157825.

167. Zhang DX, Dang X, Wu Y, Yeh YC, et al. avillin integrin is enriched in extracellular vesicles of metastatic breast cancer cells: A mechanism mediated by galectin-3. J Extracellular Vesicles. 2022;11(8):e12234.

168. Lee PJ, Sui YH, Liu TT, Tsang NM, Huang CH, Lin TY, Chang KP, Liu SC. Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPa signaling in fibroblasts. J Exp Clin Cancer Res. 2022;41(1):254.

169. Rao VS, Gu Q, Tzschentschke S, Lin K, Ganig N, Theipaysone ML, Wong FC, Polster H, Seifert L, Seifert AM, et al. Extracellular TIMP-1 is a non-invasive independent prognostic marker and potential therapeutic target in colorectal metastases. Oncogene. 2022;41(12):1809–20.

170. Ahn S, Kwon A, Huh YH, Rhee S, Song WK. Tumor-derived miR-130b-3p induces cancer-associated fibroblast activation by targeting SPINK9 in luminal A breast cancer. Oncogenesis. 2022;11(1):47.

171. Zhang C, Wang XY, Zhang P, He TC, Han JH, Zhang R, Lin J, Fan J, Lu L, Zhu WW, et al. Cancer-derived exosomal hspc111 promotes colorectal cancer liver metastasis by reprogramming lipid metabolism in cancer-associated fibroblasts. Cell Death Dis. 2022;13(1):157.

172. Wang D, Wang X, Song Y, Si M, Sun Y, Liu X, Cui J, Qu X, Yu X. Exosomal miR-164a-5p and miR-155-5p promote CXCL12/CXCR7-induced metastasis of colorectal cancer by crossstalk with cancer-associated fibroblasts. Cell Death Dis. 2022;13(4):380.

173. Loukou T, Hayashi Y, Tsuji Y, Sakata S, Sakatani A, Kimura K, Umera R, Kato M, Saiki H, Shinsaki S, et al. Suppression of autophagy promotes fibroblast activation in p53-deficient colorectal cancer cells. Sci Rep. 2021;11(1):19524.

174. Jiang Y, Wang K, Lu X, Wang Y, Chen J. Cancer-associated fibroblasts-derived exosomes promotes lung cancer progression by OIP5-A51/miR-142-5p-PO-LI axis. Mol Immunol. 2021;140:47–58.

175. Chen H, Zhao L, Meng Y, Qian X, Fan Y, Zhang W, Cui L, Lin F, Chen B, Xu L, et al. Sulforylurea receptor 1-expressing cancer cells induce cancer-associated fibroblasts to promote non-small cell lung cancer progression. Cancer Lett. 2022;536:215611.

176. Lu L, Huang J, Mo J, Da X, Li Q, Fan M, Lu H. Exosomal IncRNA TUG1 from cancer-associated fibroblasts promotes lung cancer cell migration, invasion, and glycosylation by regulating the miR-524-3p/SIX1 axis. Cell Mol Biol Lett. 2022;71(1):17.

177. Zhang Y, Zhao J, Ding M, Su Y, Cui D, Jiang C, Zhao S, Jia G, Wang X, Ruan Y, et al. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis. J Exp Clin Cancer Res. 2020;39(1):282.

178. Tan D, Li G, Zhang P, Peng C, He B. LncRNA SNHG12 in extracellular vesicles derived from carcinoma-associated fibroblasts promotes cisplatin resistance in non-small cell lung cancer cells. Bioengineering. 2022;13(1):1838–57.

179. Yang K, Zhang F, Luo B, Qu Z. CAFs-derived small extracellular vesicles circ-HBP2/L2 promotes proliferation and metastasis of colorectal cancer via miR-664d-5p/HMG8 pathway. Cancer Biol Ther. 2021;22(3):1404–16.

180. Dai X, Xie Y, Dong M. Cancer-associated fibroblasts derived extracellular vesicles promote angiogenesis of colorectal adenocarcinoma cells through miR-135b-5p/FOXO1 axis. Cancer Biol Ther. 2022;23(1):76–88.

181. Richards KE, Xiao W, Hill R, On Behalf Of The Us Cancer pancreas Research T. Cancer-associated fibroblasts confer gemcitabine resistance to pancreatic cancer cells through PTEN-targeting miRNAs in exosomes. Cancers. 2022;14(1):2812.

182. Han Y, Qian X, Xu T, Shi Y. Carcinoma-associated fibroblasts release miRNA-331-3p containing extracellular vesicles to exacerbate the development of pancreatic cancer via the SCARAS-FAK axis. Cancer Biol Ther. 2022;23(1):378–92.

183. Shi L, Zhu W, Huang Y, Zhou L, Wang S, Chen S, Zhang B, Ke B. Cancer-associated fibroblast-derived exosomal miRNA-20a suppresses the PTEN/PI3K-AKT pathway to promote the progression and chemoresistance of non-small cell lung cancer. Clin Transl Med. 2022;12(7):e899.

184. Pan S, Deng Y, Fu J, Zhang Y, Zhang Z, Qin X. N6-methyladenosine upregulates miR-181d-5p in exosomes derived from cancer-associated fibroblasts to inhibit S-FU sensitivity by targeting NCALD in colorectal cancer. Int J Oncol. 2022;60(2):1601.
development via activation of PI3K/AKT and downstream signaling pathways. Mol Carcinog. 2022. https://doi.org/10.1002/mc.23445.

195. Yan Z, Sheng Z, Zheng Y, Feng R, Xiao Q, Shi L, Li H, Yin C, Luo H, Hao C, et al. Cancer-associated fibroblast-derived exosomal miR-18b promotes breast cancer invasion and metastasis by regulating TCEAL7. Cell Death Dis. 2021;12(12):1120.

196. Zhao J, Lin H, Huang K, Li S. Cancer-associated fibroblasts-derived extracellular vesicles carrying lncRNA SNHG3 facilitate colorectal cancer cell proliferation via the miR-34b-5p/HuR/FOXC6 axis. Cell Death Discov. 2022;8(1):346.

197. Wang S, Fu P, Cao Y, Ma J, Yang X, Yu Z, Yang Y. Cancer associated fibroblasts secreted exosomal miR-1290 contributes to prostate cancer cell growth and metastasis via targeting GSK3β. Cell Death Discov. 2022;8(1):371.

198. Fang F, Guo C, Zheng W, Wang Q, Zhou L. Exosome-mediated transfer of miR-1323 from cancer-associated fibroblasts confers radioresistance of C33A cells by targeting PABPN1 and activating Wnt/β-catenin signaling pathway in cervical cancer. Reprod Sci. 2022;29(6):1809–21.

199. Shi Z, Jiang T, Cao B, Sun X, Liu J. CAF-derived exosomes deliver LINC01410 to promote epithelial–mesenchymal transition of esophageal squamous cell carcinoma. Exp Cell Res. 2022;412(2):113033.

200. Qin W, Wang L, Tian H, Wu X, Xiao C, Pan Y, Fan M, Tai Y, Liu W, Zhang Q, et al. CAF-derived exosomes transmitted Gremlin-1 promotes cancer progression and decreases the sensitivity of hepatoma cells to sorafenib. Mol Carcinog. 2022;61(8):764–75.

201. Wang Y, Li T, Yang L, Zhang X, Wang X, Su X, Ji C, Wang Z. Cancer-associated fibroblast-released extracellular vesicles carrying miR-199a-5p induces the progression of gastric cancer through regulation of FKBPS-mediated AKT1/mTORC1 signaling pathway. Cell Cycle. 2022. https://doi.org/10.1080/15384101.2022.2105092.

202. Yin H, Yu S, Xie Y, Dai X, Dong M, Sheng C, Hu J. Cancer-associated fibroblasts-derived exosomes upregulate microRNA-135b-5p to promote colorectal cancer cell growth and angiogenesis by inhibiting thioredoxin-interacting protein. Cell Signal. 2021;84:110029.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.